Sep 13,2021

CureApp Hypertension Therapeutics App: Clinical Trial Results Announced at ESC Congress 2021 and Published in the European Heart Journal

This clinical trial ran from January 2020 to December 2020 evaluating the efficacy and safety of the CureApp, therapeutic app for patients with essential hypertension, and represented the world’s first trial of a therapeutic app for the purpose of regulatory approval in the field of hypertension. It was performed as a comparative study of two groups, a control group who received guidance on lifestyle changes based on the Guidelines for the Management of Hypertension 2019, and an intervention group who used this therapeutic app in addition to applying lifestyle changes in accordance with said Guidelines.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 14,2021

Improvements in medication adherence maintained during COVID-19 pandemic

According to data presented at the European Respiratory Society International Congress 2021, early improvements in controller medication adherence steadily increased among 20,908 Propeller users throughout 2020. In the last week of January 2020, before the designation of a global pandemic, mean adherence was at 55%. As the year progressed, Propeller continued to observe an upward trend with a peak of 62% in the last week of November. Propeller data also suggested an increase in the proportion of patients who adhered to their medications. The proportion of patients exhibiting at least 75% daily adherence increased from approximately 47% to 56% between January and December of 2020

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Sep 16,2021

Pear Therapeutics Announces Publication of Real-World Data Showing Improved Clinical Outcomes with a Subsequent Prescription of reSET-O

Pear Therapeutics, Inc., today announced publication of real-world data evaluating the impact of reSET-O for the treatment of opioid use disorder (OUD) on patients treated for 24 weeks. Patients evaluated were in outpatient treatment and were prescribed buprenorphine at clinician-determined doses, routes of administration and regimens. In the 24-week cohort, 94.4% met the responder rate of being abstinent for at least 80% of the weeks of treatment. Abstinence was measured based on negative UDS or self-reports. 91.4% of patients were retained in treatment at the end of the second prescription period (weeks 21-24 of 24). Taken together with prior publications, these results suggest that reSET-O can provide clinical and economic benefit, that patients continue to have high-rates of engagement through 24 weeks of treatment, and that benefit can by enhanced significantly by a “refill” prescription of the PDT.

CLINICAL STUDY

#pdt

View Analyst & Ambassador Comments
Go to original news
Sep 29,2021

Topline Results from Shionogi Phase 2 Study in Japan Show Akili’s Digital Treatment Was Well-received and Improved Inattention Symptoms in Children with ADHD

Akili Interactive (“Akili”), a leading cognitive medicine company improving health through game-changing technologies, today announced topline results of a Phase 2 study of SDT-001 (Japanese version of AKL-T01), a digital therapeutic designed to improve measures of attention in children diagnosed with attention-deficit/hyperactivity disorder (ADHD). The study, conducted by Akili partner Shionogi & Co., Ltd. (“Shionogi”), was designed to evaluate the feasibility, safety and efficacy of the digital therapeutic in children with ADHD and to inform the design of a potential pivotal study.

CLINICAL STUDY

#cbt

View Analyst & Ambassador Comments
Go to original news
Mar 29,2021

Full results of EndeavorRx adjunct trial show longer benefits with or without stimulant therapy

Akili Interactive has published the full data from its STARS-ADHD Adjunctive trial. The data builds upon the company's pivotal study of AKL-T01 (now available as EndeavorRx) and suggests the videogame-like digital therapeutic delivers benefits with or without accompanying stimulant medication, and that they persist up to one month following the treatment.

CLINICAL STUDY

#software

View Analyst & Ambassador Comments
Go to original news
Mar 02,2021

DarioHealth Study Examines Connection Between Personalization and Sustained Behavior Change in Digital Health

DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, today announced the results of a new clinical study that have been published in the Journal of Medical Internet Research (JMIR) Diabetes. The paper is titled "Role of Digital Engagement in Diabetes Care Beyond Measurement: Retrospective Cohort Study."

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Mar 10,2021

Cognito Therapeutics touts positive Phase 2 results for device-delivered Alzheimer's treatment

Yesterday Cognito Therapeutics, a startup using visual and auditory stimulation to treat neurodegenerative disorders, announced Phase 2 trial results suggesting its gamma frequency neuromodulation therapy slowed declines in memory and cognition among mild-to-moderate Alzheimer's disease patients. The OVERTURE study, a multi-center, randomized controlled trial, enrolled 76 such patients aged 50 years or older beginning in 2018. These participants were randomized to receive either Cognito's audio-visual stimulation treatment or a sham stimulation for one hour each day in their home.

CLINICAL STUDY

#cbt

View Analyst & Ambassador Comments
Go to original news
Apr 09,2021

New research shows Propeller improves outcomes for patients with high burden of COPD

At Propeller, we want to make this information accessible to patients and their clinicians so they can make informed decisions and understand long-term trends in the patient’s condition. To do so, we prompt patients with COPD to take the CAT once a month in the Propeller app and share the results with patients and their providers. By combining CAT scores and the objective medication usage data Propeller collects, we can better understand the patient’s COPD status and the need for further intervention. In a new article published in Frontiers in Digital Health, we observed significant, parallel improvements in CAT scores and rescue inhaler use among 611 patients with COPD using the Propeller platform.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
May 11,2021

Large-Scale Study Finds Mental Health App Forms Bond With Users, Marking Key Evolution in Digital Therapeutics

Woebot Health, a pioneer in the development of relational technologies and tools to support mental health, today announced that the results of its most recent study, titled “Evidence of human-level bonds established with a digital conversational agent,” have been published in the open access journal JMIR Formative Research. Among a large sample of 36,070 users, the study provides evidence that Woebot, the company’s proprietary relational agent, establishes a therapeutic bond with users—a construct long thought to be the unique domain of human-to-human interactions. The findings are unprecedented in a commercialized product and could mark a foundational step toward purely digital solutions’ ability to help meet surging demand for mental health care.

CLINICAL STUDY

#chatbot

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
May 27,2021

DarioHealth touts research on digital therapeutics for diabetes patients

New York-based DarioHealth published a new study through a letter to the editor in the Journal of Diabetes Science and Technology, according to a news release. The study observed participants using DarioHealth’s digital therapeutics for diabetes management, monitoring for both clinical and self-reported impact.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY